The optoenergetic activation of mt-EcGAPR suppresses the ER stress–ATF6–pyroptosis axis caused by mitochondrial dysfunction, positioning it as a promising therapeutic agent for not only glaucoma but also other retinal neurodegenerative diseases, such as diabetic retinopathy. The gene discussed is ATF6; the disease is glaucoma.